New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:49 EDTURBN, OCLR, CYS, PPHM, HUSA, MLNK, HTZOn The Fly: After Hours Movers
HIGHER: Urban Outfitters (URBN), up 7% after the company's 10-Q filing outlined expansion plans, positive Q4 SSS... Oclaro (OCLR), up 3% after announcing preliminary merger litigation settlement... CYS Investments (CYS), up 2% after announcing 52c per share special dividend... DOWN AFTER EARNINGS: Peregrine Pharmaceuticals (PPHM), down 3%... ALSO LOWER: Houston American Energy (HUSA), down 53% after abandoning the Zorro Gris #1 well... ModusLink (MLNK), down 5% after announcing it would delay the filing of its 10-Q... Hertz Global (HTZ), down 3% after announcing the sale of 50M shares of common stock by holders.
News For URBN;OCLR;CYS;PPHM;HUSA;MLNK;HTZ From The Last 14 Days
Check below for free stories on URBN;OCLR;CYS;PPHM;HUSA;MLNK;HTZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2014
08:02 EDTHTZHertz awarded three year contract by New Zealand government
Subscribe for More Information
April 9, 2014
08:38 EDTHTZHertz expands Denver oil field equipment rental operations to Wyoming
Subscribe for More Information
08:05 EDTURBNUrban Outfitters long-term outlook positive, says Wedbush
Subscribe for More Information
April 8, 2014
07:22 EDTPPHMBiotech Industry Organization to hold a conference
Subscribe for More Information
April 7, 2014
08:29 EDTPPHMPeregrine reports supporting data for combining bavituximab with irradiation
Peregrine Pharmaceuticals announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy, or SBRT, showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer, or NSCLC, compared to irradiation alone. These data were presented yesterday at the 105th Annual Meeting of the American Association for Cancer Research, or AACR, being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial.
07:27 EDTPPHMAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use